Thursday , June 21 2018
Home / Conditions (page 120)

Conditions

CONDITIONS

FDA Advisors Recommend Approval of Obesity Drug Qnexa

The FDA Endocrinologic and Metabolic Drugs Advisory Committee voted overwhelmingly (20 to 2) in favor of approving the obesity drug Qnexa (Vivus, Inc.), a combination of phentermine and controlled-release topiramate. Qnexa could be the first prescription drug for obesity to reach the market since 1999.…

Read More »